The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
The Thalassemia Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The incidence and impact of early-onset high-risk clonal hematopoiesis in sickle cell disease
Lachelle Weeks, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, provides insight into a study investigating clonal hematopoiesis (CH) in sickle cell disease (SCD), highlighting that patients with SCD have a higher incidence of early-onset high-risk CH involving DNA damage response pathway mutations compared to controls or individuals with beta-thalassemia. Dr Weeks notes that these findings provide a possible mechanism for the elevated risk of myeloid leukemias in SCD and therapy-related leukemias as a complication of curative therapies. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
